CINCINNATI, Jan. 7 Kendle (Nasdaq: KNDL) aleading, global full-service clinical research organization, today announcedCandace Kendle, PharmD, Chairman and CEO, will participate in the 27th AnnualJ.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12, 2009 at4:30 p.m. Pacific Standard Time.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )
The public is invited to listen to a live webcast of Kendle's presentationat http://www.kendle.com (click on the link provided in the Investor Eventsand Presentations section). An archived version can be accessed approximatelythree hours following Kendle's presentation and will be available until Feb.12. Slides accompanying the presentation will be available by 4 p.m. EasternStandard Time on Jan. 12 at http://www.kendle.com under the Investor Eventsand Presentations section.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinicalresearch organization providing the full range of early- to late-stageclinical development services for the world's biopharmaceutical industry. Ourfocus is on innovative solutions that reduce cycle times for our customers andaccelerate the delivery of life-enhancing drugs to market for the benefit ofpatients worldwide. As one of the fastest-growing global providers of PhaseI-IV services, we offer experience spanning 90 countries, along withindustry-leading patient access and retention capabilities and broadtherapeutic expertise, to meet our customers' clinical development challenges.
Kendle was recognized by FORTUNE magazine as one of the 100fastest-growing companies in the United States for 2008. The company also hasbeen recognized as "Top CRO to Work With" in the CenterWatch 2007 survey ofU.S. investigative sites and was named among the top threeCROs to work with in its 2008 survey of European investigative sites.
Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from theCompany's Web site at http://www.kendle.com .
SOURCE Kendle International Inc.